Ivabradine Glenmark

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Glenmark (Ivabradine)

Q: Who should not use Ivabradine?

Ivabradine is contraindicated in patients with sick sinus syndrome, second‑degree atrioventricular block, severe hepatic impairment, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with a resting heart rate below 50 bpm before treatment initiation.

Ivabradine, the active ingredient in Ivabradine Glenmark, is a If channel inhibitor presented as a tablet for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH India supplies Ivabradine Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across multiple markets.

Manufacturer / TM Owner

Glenmark Arzneimittel Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac If channel to reduce heart rate, providing therapeutic benefit in specific cardiovascular conditions.

Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance.
Heart failure with reduced ejection fraction: lowers heart rate, contributing to improved ventricular remodeling and reduced hospitalization risk.
Symptomatic angina (exercise‑induced): enhances functional capacity by decreasing myocardial oxygen demand.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows depolarization of pacemaker cells. This reduction in automaticity decreases heart rate without affecting myocardial contractility or ventricular repolarisation, thereby lowering cardiac oxygen consumption while preserving stroke volume.

Side Effects

Ivabradine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Bradycardia: resting heart rate may fall below 50 bpm.
Visual disturbances (phosphenes): transient luminous phenomena.
Headache: mild to moderate intensity.
Dizziness: often related to reduced heart rate.
Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

Severe bradycardia: may require medical intervention.
Atrial fibrillation: irregular heart rhythm episodes.
Symptomatic hypotension: dizziness or fainting due to low blood pressure.
Vision loss: rare but potentially permanent ocular events.
Allergic reactions: rash, pruritus, or anaphylaxis.

Precautions & Warnings

When prescribing Ivabradine, clinicians should consider several safety precautions to minimize risk.

Monitor heart rate: ensure resting heart rate remains above 50 bpm before initiation.
Avoid in severe hepatic impairment: limited metabolism may increase systemic exposure.
Use caution with concomitant beta‑blockers: additive heart‑rate lowering effect can cause profound bradycardia.
Do not use in patients with sick sinus syndrome or second‑degree AV block: risk of severe conduction disturbances.
Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Ivabradine can interact with other medicines, altering its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Ivabradine levels and risk of bradycardia.
Other heart‑rate‑lowering agents (e.g., beta‑blockers, digoxin): can cause excessive slowing of heart rate.

Moderate Interactions (Monitor Closely)

CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce Ivabradine exposure.
Verapamil: modest increase in Ivabradine plasma concentration.
Diltiazem: may elevate Ivabradine levels, requiring heart‑rate monitoring.

Frequently Asked Questions

Ivabradine Glenmark is prescribed to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction. By slowing the sinus node firing, it reduces myocardial oxygen demand and helps alleviate angina symptoms while supporting heart‑failure management.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the electrical pathway that controls the heart’s pacemaker activity. Inhibition of this current slows the spontaneous depolarisation of pacemaker cells, resulting in a lower resting heart rate without affecting contractile force.

The appropriate dose of Ivabradine Glenmark is determined by the prescribing physician based on clinical guidelines, the patient’s resting heart rate, and individual tolerance. Dosage adjustments are made during follow‑up visits to achieve the target heart‑rate range.

Safety data for Ivabradine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider.

To request Ivabradine Glenmark, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Ivabradine and beta‑blockers lower heart rate, but Ivabradine does so by selectively inhibiting the If current without affecting beta‑adrenergic receptors, so it does not influence blood pressure or contractility. Beta‑blockers have broader cardiovascular effects, including reduction of blood pressure and myocardial contractility, which may be advantageous or limiting depending on the patient’s condition.

Store Ivabradine Glenmark at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Ivabradine Glenmark is taken orally as a whole tablet, with or without food. Patients should swallow the tablet with a glass of water and avoid crushing or chewing it, as this could affect the drug’s release characteristics.

The most serious adverse events include severe bradycardia (heart rate < 50 bpm), atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may lead to permanent vision loss. Prompt medical attention is required if patients experience dizziness, fainting, palpitations, or visual changes.

Ivabradine is contraindicated in patients with sick sinus syndrome, second‑degree atrioventricular block, severe hepatic impairment, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with a resting heart rate below 50 bpm before treatment initiation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.